Back to Resource Center

Development and Preclinical Evaluation of a Dual-Drug Implant for Long-Acting HIV Prevention and Contraception

Development and Preclinical Evaluation of a Dual-Drug Implant for Long-Acting HIV Prevention and Contraception

A single-rod subcutaneous implant releasing islatravir and etonogestrel was well tolerated in rabbits and released both drugs steadily over about 90 days, although islatravir levels were below HIV-prevention targets.

August 2026

Click to view Resource

Click for full info +
Multipurpose prevention technologies (MPTs) that combine protection against HIV and unintended pregnancy can improve women’s health outcomes by simplifying use and enhancing adherence. We developed a long-acting (LA) implant for the simultaneous and sustained delivery of the antiretroviral islatravir (ISL) and the contraceptive hormone etonogestrel (ENG).

View Article


Full Info:


Resource Type:

Journal Article
Journal Article
Resource

Authors: Krovi, A., Levin, L., Gatto, G.J., Luecke, E.H., Brand, R., Swistok, A., Cottrell, M.L., Schauer, A.P., Johnson, L.M.

Health Risks(s):

  • HIV
  • Unintended Pregnancy

Product type(s):

  • ARVs
  • Hormonal
  • Implants
  • MPTs

Topic(s):

  • MPTs
  • Development

Region(s)

  • United States

Additional Keywords:

implant; islatravir; etonogestrel; preclinical

URL of resource:

https://www.mdpi.com/1999-4923/18/9/1060

Back to Resource Center